Amino Terminal Pro–B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy | Zendy

W. T. Longstreth | Zendy; Richard A. Kronmal | Zendy; John L.P. Thompson | Zendy; Robert H. Christenson | Zendy; Steven R. Levine | Zendy; Rebecca Gross | Zendy; Robin L. Brey | Zendy; Richard Buchsbaum | Zendy; Mitchell S.V. Elkind | Zendy; David Tirschwell | Zendy; Stephen L. Seliger | Zendy; J.P. Mohr | Zendy; Christopher R. deFilippi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Amino Terminal Pro–B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy

Author(s) -

W. T. Longstreth,

Richard A. Kronmal,

John L.P. Thompson,

Robert H. Christenson,

Steven R. Levine,

Rebecca Gross,

Robin L. Brey,

Richard Buchsbaum,

Mitchell S.V. Elkind,

David Tirschwell,

Stephen L. Seliger,

J.P. Mohr,

Christopher R. deFilippi

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.675942

Subject(s) - medicine , antithrombotic , natriuretic peptide , stroke (engine) , amino terminal , peptide , secondary prevention , amino acid , pharmacology , cardiology , peptide sequence , biochemistry , heart failure , mechanical engineering , engineering , chemistry , gene

Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research